| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/23/2009 | WO2009090556A2 Artificial reproduction of pharmaceutical conditions of dependency to tobacco and other addictive drugs (opiacea, psychostimulants, alcohol) by combination of nicotine and a ligand (agonist or 5 antagonist) of 5-ht1a receptors |
| 07/23/2009 | WO2009090210A2 Combination of metformin and an mtp inhibitor |
| 07/23/2009 | WO2009090010A1 Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| 07/23/2009 | WO2009089822A2 Use of an acetylsalicylic acid salt for the treatment of viral infections |
| 07/23/2009 | WO2009089635A1 Treating neurodegenerative diseases with progranulin (pgrn) |
| 07/23/2009 | WO2009089620A1 Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
| 07/23/2009 | WO2009071095A3 Prevention of hyperthermia subsequent to hypothermia treatment of ischemia |
| 07/23/2009 | WO2009068906A3 Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| 07/23/2009 | WO2009016358A3 Pharmaceutical compositions and process for making them |
| 07/23/2009 | WO2009000843A3 Treatment of heart failure in non-human animal mammals by an aldosterone antagonist |
| 07/23/2009 | WO2009000551A8 Use of a synergistic composition as a therapeutic agent or disinfectant |
| 07/23/2009 | WO2008156550A3 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| 07/23/2009 | WO2007131182A8 System for high production of natural and personalized interferons |
| 07/23/2009 | WO2007116409A8 Improved vaccines comprising multimeric hsp60 peptide carriers |
| 07/23/2009 | US20090186908 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 07/23/2009 | US20090186871 Tyrosine kinase inhibitors |
| 07/23/2009 | US20090186850 Peritoneal dialysis method |
| 07/23/2009 | US20090186038 Methods of Preventing or Treating Respiratory Conditions |
| 07/23/2009 | US20090186037 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 07/23/2009 | US20090186010 Methods for the identification of ikkalfa function and other genes useful for treatment of inflammatory diseases |
| 07/23/2009 | US20090186001 Methods for Treating Ischemic Tissue |
| 07/23/2009 | US20090185983 Aqueous medicament preparations for the production of propellant gas-free aerosols |
| 07/23/2009 | US20090185979 Integrin Heterodimer and an Alpha Subunit Thereof |
| 07/23/2009 | CA2714286A1 The use of an acetylsalicylic acid salt for treating viral infections |
| 07/23/2009 | CA2712614A1 Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
| 07/23/2009 | CA2712404A1 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| 07/23/2009 | CA2712276A1 Treating neurodegenerative diseases with progranulin (pgrn) |
| 07/23/2009 | CA2712057A1 Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
| 07/23/2009 | CA2618380A1 Feed additive and uses thereof |
| 07/22/2009 | EP2080804A1 Modified cytokines for use in cancer therapy |
| 07/22/2009 | EP2080523A1 Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| 07/22/2009 | EP2079840A1 Immunotox n fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| 07/22/2009 | EP2079485A2 Phenylpropionamide compounds and the use thereof |
| 07/22/2009 | EP2079477A2 Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses |
| 07/22/2009 | EP2079470A2 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
| 07/22/2009 | EP2079469A2 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema |
| 07/22/2009 | EP2079468A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 07/22/2009 | EP2079452A1 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
| 07/22/2009 | EP2079447A1 Pharmaceutical solid dosage forms comprising compounds micro-embedded in ionic water-insoluble polymers |
| 07/22/2009 | EP2006377A9 Novel tumor antigen peptides |
| 07/22/2009 | EP1738253A4 Systems and methods for providing a stem cell bank |
| 07/22/2009 | EP1663395B1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 07/22/2009 | EP1531855A4 Treatment of bone disorders with skeletal anabolic drugs |
| 07/22/2009 | EP1503988B1 Fredericamycin derivatives |
| 07/22/2009 | EP1499290B1 Warming and nonirritating lubricant compositions |
| 07/22/2009 | EP1458413B1 Pharmaceutical compositions based on azetidine derivatives |
| 07/22/2009 | EP1453528B1 Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 07/22/2009 | EP1379224B1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 07/22/2009 | EP1244455B1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 07/22/2009 | EP1220922B1 Method of identifying a compound with efficacy in the treatment of chronic inflammatory diseases |
| 07/22/2009 | EP1220689B1 Medicament for the treatment of chronic fatigue syndrome associated with fibromyalgia and irritable bowel syndrome. |
| 07/22/2009 | CN101489591A Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction |
| 07/22/2009 | CN101485885A Protein phosphatase PPM1E used as target for treating disease as well as use thereof and siRNA |
| 07/22/2009 | CN100516203C In vitro cell culturing method |
| 07/22/2009 | CN100516034C Inhibitors of aspartyl protease |
| 07/22/2009 | CN100515497C Liposomal delivery of vitamin E based compounds |
| 07/22/2009 | CN100515419C Substituted benzazoles and its application as inhibitors of Raf kinase |
| 07/22/2009 | CN100515416C A herbal molecule as potential anti-leukemic drug |
| 07/21/2009 | US7563881 Nucleic acid encoding polypeptide involved in cellular entrance of the PRRS virus |
| 07/21/2009 | US7563824 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 07/21/2009 | US7563822 active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion |
| 07/21/2009 | US7563810 Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| 07/21/2009 | US7563790 Pyridazine derivatives |
| 07/21/2009 | US7563789 1-Adamantyl chalcones for the treatment of proliferative disorders |
| 07/21/2009 | US7563774 Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 07/21/2009 | US7563765 Histidine-rich glycoprotein |
| 07/21/2009 | US7563593 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 07/21/2009 | US7563586 Tetrodotoxin resistant membrane protein for use in pain management |
| 07/21/2009 | US7563582 Identifying chemical compounds which are capable of modulating the interaction between vasodilator-stimulated phosphoprotein and zyxin |
| 07/21/2009 | US7563458 Nutritional compositions for nutritional management of patients with liver disease |
| 07/21/2009 | US7563446 Administering a phosphatidylserine/polypeptide conjugate with polypeptide being bovine serum albumin, keyhole limpet hemocyanin, bovine gamma-globulin, diphtheria toxin, or beta 2-glycoprotein |
| 07/21/2009 | US7563445 Tumor antigens/vaccines such as cytotoxic T-lymphocytes (CTL) |
| 07/21/2009 | CA2409845C Active substance combination containing a compound with an opioid effect and at least one further compound of formula i |
| 07/21/2009 | CA2387486C Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/21/2009 | CA2348988C Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor |
| 07/16/2009 | WO2009089260A2 Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| 07/16/2009 | WO2009089082A1 Trpa1 antagonists |
| 07/16/2009 | WO2009088553A1 Dry powder drug delivery formulations, methods of use, and devices therefore |
| 07/16/2009 | WO2009088063A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases |
| 07/16/2009 | WO2009088006A1 Combined pharmaceutical agent |
| 07/16/2009 | WO2009087900A1 Pharmaceutical agent for prevention or treatment of diseases accompanied by intraocular vascular hyperpermeability |
| 07/16/2009 | WO2009087474A2 Agonists for antimicrobial peptide systems |
| 07/16/2009 | WO2009087351A1 Use of cannabinoids in combination with an anti-psychotic medicament |
| 07/16/2009 | WO2009086952A2 Compositions for the treatment of degenerative articular diseases |
| 07/16/2009 | WO2009086614A1 Method and application of synbiotic food/feed composition for humans and animals |
| 07/16/2009 | WO2009067791A4 Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| 07/16/2009 | WO2009058005A3 Unit dosage for brain health |
| 07/16/2009 | WO2009045795A3 Galenical formulations of aliskiren and valsartan |
| 07/16/2009 | WO2009045720A3 Electricity-generating particulates and the use thereof |
| 07/16/2009 | WO2009037539A3 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 07/16/2009 | WO2009020481A3 Therapeutic compositions and methods for treating gram-negative bacterial infections |
| 07/16/2009 | WO2008132717A3 Compositions and methods for cell killing |
| 07/16/2009 | WO2008128169A8 Sparc and methods of use thereof |
| 07/16/2009 | WO2008125903A3 Method of inhibiting an undesired immune response |
| 07/16/2009 | WO2008125366A3 Treatment of autoimmune diseases |
| 07/16/2009 | WO2005011680A8 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 07/16/2009 | US20090182037 Cognitive Function |
| 07/16/2009 | US20090181978 5-ht1a receptor subtype agonist |
| 07/16/2009 | US20090181969 Hypotensive Lipid And Timolol Compositions And Methods Of Using Same |
| 07/16/2009 | US20090181100 Dry powder aerosols of Nanoparticulate drugs |